Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial.
Yen Y, Chow W, Leong L, Margolin K, Morgan R, Raschko J, Shibata S, Somlo G, Twardowski P, Frankel P, Longmate J, Synold T, Newman EM, Lenz HJ, Gandara D, Doroshow JH. Yen Y, et al. Among authors: longmate j. Cancer Chemother Pharmacol. 2002 Nov;50(5):353-9. doi: 10.1007/s00280-002-0492-9. Epub 2002 Sep 12. Cancer Chemother Pharmacol. 2002. PMID: 12439592 Clinical Trial.
Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial.
Yen Y, Lim DW, Chung V, Morgan RJ, Leong LA, Shibata SI, Wagman LD, Marx H, Chu PG, Longmate JA, Lenz HJ, Ramanathan RK, Belani CP, Gandara DR. Yen Y, et al. Among authors: longmate ja. Am J Clin Oncol. 2008 Aug;31(4):317-22. doi: 10.1097/COC.0b013e318162f57d. Am J Clin Oncol. 2008. PMID: 18845988 Clinical Trial.
Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.
Morgan RJ, Synold TW, Longmate JA, Quinn DI, Gandara D, Lenz HJ, Ruel C, Xi B, Lewis MD, Colevas AD, Doroshow J, Newman EM. Morgan RJ, et al. Among authors: longmate ja. Cancer Chemother Pharmacol. 2015 Nov;76(5):897-907. doi: 10.1007/s00280-015-2868-7. Epub 2015 Sep 11. Cancer Chemother Pharmacol. 2015. PMID: 26362045 Free PMC article. Clinical Trial.
Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer.
Morgan RJ Jr, Synold TW, Gandara D, Muggia F, Scudder S, Reed E, Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S, McGonigle K, Longmate J, Yen Y, Chow W, Somlo G, Carroll M, Doroshow JH. Morgan RJ Jr, et al. Among authors: longmate j. Cancer Chemother Pharmacol. 2004 Oct;54(4):283-9. doi: 10.1007/s00280-004-0818-x. Epub 2004 Jun 4. Cancer Chemother Pharmacol. 2004. PMID: 15184995 Clinical Trial.
Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial.
Lara PN Jr, Gumerlock PH, Mack PC, Lau DH, Gandour-Edwards R, Edelman MJ, Albain KS, Law LY, Longmate J, Frankel P, Reddy GP, Israel V, Doroshow JH, Gandara DR. Lara PN Jr, et al. Among authors: longmate j. Clin Lung Cancer. 2004 Sep;6(2):102-7. doi: 10.3816/CLC.2004.n.023. Clin Lung Cancer. 2004. PMID: 15476595 Clinical Trial.
A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.
Chao J, Synold TW, Morgan RJ Jr, Kunos C, Longmate J, Lenz HJ, Lim D, Shibata S, Chung V, Stoller RG, Belani CP, Gandara DR, McNamara M, Gitlitz BJ, Lau DH, Ramalingam SS, Davies A, Espinoza-Delgado I, Newman EM, Yen Y. Chao J, et al. Among authors: longmate j. Cancer Chemother Pharmacol. 2012 Mar;69(3):835-43. doi: 10.1007/s00280-011-1779-5. Epub 2011 Nov 22. Cancer Chemother Pharmacol. 2012. PMID: 22105720 Free PMC article. Clinical Trial.
Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Chow WA, Synold TW, Tetef ML, Longmate J, Frankel P, Lawrence J, Al-Khadimi Z, Leong L, Lim D, Margolin K, Morgan RJ Jr, Raschko J, Shibata S, Somlo G, Twardowski P, Yen Y, Doroshow JH. Chow WA, et al. Among authors: longmate j. Cancer Chemother Pharmacol. 2004 Sep;54(3):241-8. doi: 10.1007/s00280-004-0803-4. Epub 2004 Jun 2. Cancer Chemother Pharmacol. 2004. PMID: 15173955 Clinical Trial.
131 results